dipyridamole has been researched along with Vasculitis in 9 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess red blood cell deformability (RCD) in patients with rheumatoid arthritis (RA) without extraarticular manifestations and in RA with vasculitic complications (RV), and to assess whether in vitro dipyridamole improves RCD." | 7.69 | Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole. ( Belch, JJ; Lau, CS; Saniabadi, AR, 1995) |
| "Eight patients with livedo vasculitis of four to 30 years' duration that was unresponsive to a variety of medications were treated with pentoxifylline." | 7.67 | Livedo vasculitis. Therapy with pentoxifylline. ( Sams, WM, 1988) |
| "To assess red blood cell deformability (RCD) in patients with rheumatoid arthritis (RA) without extraarticular manifestations and in RA with vasculitic complications (RV), and to assess whether in vitro dipyridamole improves RCD." | 3.69 | Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole. ( Belch, JJ; Lau, CS; Saniabadi, AR, 1995) |
| "Eight patients with livedo vasculitis of four to 30 years' duration that was unresponsive to a variety of medications were treated with pentoxifylline." | 3.67 | Livedo vasculitis. Therapy with pentoxifylline. ( Sams, WM, 1988) |
| "Current vasculitis was also associated with abnormal scintigraphy." | 1.32 | Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. ( Barbieri, A; Leite, WA; Oliveira Filho, JA; Sato, EI; Sella, EM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caltik, A | 1 |
| Demircin, G | 1 |
| Bülbül, M | 1 |
| Erdogan, O | 1 |
| Akyüz, SG | 1 |
| Arda, N | 1 |
| De Caterina, R | 1 |
| Massaro, M | 1 |
| Scoditti, E | 1 |
| Annunziata Carluccio, M | 1 |
| Sella, EM | 1 |
| Sato, EI | 1 |
| Leite, WA | 1 |
| Oliveira Filho, JA | 1 |
| Barbieri, A | 1 |
| Kocheril, SV | 1 |
| Blaivas, M | 1 |
| Appleton, BE | 1 |
| McCune, WJ | 1 |
| Ike, RW | 1 |
| Kern, AB | 1 |
| Drucker, CR | 1 |
| Duncan, WC | 1 |
| Lau, CS | 1 |
| Saniabadi, AR | 1 |
| Belch, JJ | 1 |
| Suarez, SM | 1 |
| Paller, AS | 1 |
| Sams, WM | 1 |
1 review available for dipyridamole and Vasculitis
| Article | Year |
|---|---|
Pharmacological modulation of vascular inflammation in atherothrombosis.
Topics: Atherosclerosis; Biomarkers; Dipyridamole; Endothelium; Humans; Inflammation Mediators; Models, Card | 2010 |
8 other studies available for dipyridamole and Vasculitis
| Article | Year |
|---|---|
An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy.
Topics: Administration, Oral; Adolescent; Antibodies, Antinuclear; Azathioprine; Cyclophosphamide; Dipyridam | 2013 |
Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Chi-Square Distribution; Cholesterol, HDL; Coronary Disease; Diabet | 2003 |
Degos' disease mimicking vasculitis.
Topics: Abdominal Pain; Diagnosis, Differential; Dipyridamole; Drug Administration Schedule; Fatal Outcome; | 2004 |
Atrophie blanche. Report of two patients treated with aspirin and dipyridamole.
Topics: Aged; Aspirin; Atrophy; Dipyridamole; Female; Humans; Middle Aged; Platelet Aggregation; Skin; Vascu | 1982 |
Antiplatelet therapy in atrophie blanche and livedo vasculitis.
Topics: Adult; Aged; Aspirin; Atrophy; Blood Platelets; Dipyridamole; Female; Humans; Male; Middle Aged; Pla | 1982 |
Reduced red blood cell deformability in patients with rheumatoid vasculitis. Improvement after in vitro treatment with dipyridamole.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dipyridamole; Erythrocyte Deformability; Female; Filtration; Hum | 1995 |
Atrophie blanche with onset in childhood.
Topics: Aspirin; Child; Dipyridamole; Drug Therapy, Combination; Humans; Male; Skin Diseases, Vascular; Vasc | 1993 |
Livedo vasculitis. Therapy with pentoxifylline.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ma | 1988 |